Blinatumomab (Genetical Recombination) (38.5 μg/1 vial) 153 vials,and 49 other contracts

2026-11-03

Official in charge of disbursement of the procuring entity : Yuji Nishikawa, President, Asahikawa Medical University Classification of the products to be procured : Nature and quantity of the products to be purchased : A Blinatumomab (Genetical Recombination) (38. μg/ vial) 15 vials B Enfortumab Vedotin (Genetical Recombination) (33. mg/ vial) 44 vials C Durvalumab (Genetical Recombination) (50 mg/1 mL/ vial) 58 vials D Fulvestrant (25 mg/ mL/ syringes/ case) 83 cases E Epcoritamab (Genetical Recombination) (4 mg/0. mL/ vial) 4 vials F Risankizumab (Genetical Recombination) (36 mg/2. mL/ kit) 14 kits G Risankizumab (Genetical Recombination) (7 mg/0.8 mL/ syringe) 30 syringes H Tarlatamab (Genetical Recombination) (1 mg/ vial) 3 vials I Efgartigimod Alfa (Genetical Recombination)・Vorhyaluronidase Alfa (Genetical Recombination) (100 mg/5. mL/ vial・1120 units/5. mL/ vial) 9 vials J Efgartigimod Alfa (Genetical Recombination) (40 mg/2 mL/ vial) 6 vials K Ravulizumab (Genetical Recombination) (30 mg/ mL/ vial) 19 vials L Sacituzumab Govitecan (Genetical Recombination) (20 mg/ vial) 19 vials M Axicabtagene ciloleucel ( bag/ case) case N Mepolizumab (Genetical Recombination) (10 mg/ mL/ kit) 21 kits O Avalglucosidase Alfa (Genetical Recombination) (10 mg/ vial) 23 vials P Tildrakizumab (Genetical Recombination) (10 mg/ vial) 5 syringes Q Canakinumab (Genetical Recombination) (15 mg/ vial) 19 vials R Onasemnogene abeparvove ( set) set Nusinersen Sodium (12.6 mg/ mL/ vial) vials T Elranatamab (Genetical Recombination) (7 mg/1. mL/ vial) 11 vials U lisocabtagene maraleuce ( set/ case) case Ⅴ Pomalidomide ( mg/ capsules/ case) 9 cases W Avelumab (Genetical Recombination) (20 mg/ vial) 28 vials X Daratumumab (Genetical Recombination)・Vorhyaluronidase Alfa (Genetical Recombination) (180 mg/1 mL/ vial・3000 units/1 mL/ vial) 37 vials Y Guselkumab (Genetical Recombination) (10 mg/ mL/ syringe) 15 syringes Z Pegfilgrastim (Genetical Recombination) (3.6mg/0.36mL/1kit) 328kits AA Pegfilgrastim (Genetical Recombination) (3. mg/0.3 mL/ syringe) 35 syringes AB Aflibercept (Genetical Recombina tion) (21.0 mg/0.18 mL/ kit) 34 kits AC Nivolumab (Genetical Recombina tion) (24 mg/2 mL/ vial) 111 vials AD Carfilzomib (4 mg/ syringe) 27 syringes AE Dinutuximab (Genetical Recombination) (17. mg/ mL/ vial) 24vials AF Paclitaxel (10 mg/ vial) 142 vials AG Trastuzumab Deruxtecan (Genetical Recombination) (10 mg/ vial) 62 vials AH Datopotamab Deruxtecan (Genetical Recombination) (10 mg/ vial) 26 vials AI Pertuzumab (Genetical Recombina tion)・Trastuzumab (Genetical Recombination)・Vorhyaluronidase Alfa (Genetical Recombination) (60 mg/1 mL/ vial) (60 mg/1 mL/ vial) (2000 units/1 mL/ vial) 55 vials AJ Polatuzumab Vedotin (Genetical Recombination) (3 mg/ vial) 46 vials AK Atezolizumab (Genetical Recombination) (120 mg/2 mL/ vial) 18 vials AL Satralizumab (Genetical Recombination) (12 mg/ mL/ syringe) 5 syringes AM Trastuzumab Emtansine (Genetical Recombination) (10 mg/ vial) 17 vials AN Faricimab (Genetical Recombination) (2 mg/0.17 mL/ syringe) 17 syringes AO Ustekinumab (Genetical Recombination) (4 mg/0. mL/ syringe) 64 syringes AP Inebilizumab (Genetical Recombination) (10 mg/1 mL/ vials/ 1case) cases AQ Infliximab (Genetical Recombination) (10 mg/ vial) 60 vials AR Ramucirumab (Genetical Recombination) (50 mg/5 mL/ vial) 12 vials A Ixekizumab (Genetical Recombination) (8 mg/ syringe/ kit) 30 kits AT Brentuximab Vedotin (Genetical Recombination) (5 mg/ vial) 6 vials AU Leuprorelin Acetate (22. mg/ syringe) 37 syringes AV Pembrolizumab (Genetical Recombination) (10 mg/ mL/ vial) 246 vials AW Sugammadex Sodium (200mg/2mL/ 1 syringe/ case) 45 cases AX SAPIEN Ultra RESILIA System (S3URCM23J 23mm for Aorti valve) or its equivalent 2 sets AY SAPIEN Ultra RESILIA System (S3URCM26J 2 mm for Aorti valve) or its equivalent 1 sets AZ SOUNDSTAR eco Catheter (1043923 8Fr 90cm for GE Healthcare) or its equivalent 9 pieces BA OCTARAY (D16090 7. Fr effective length 11 cm 48+ poles spacing 3-3-3-3-3mm) or its equivalent 9 pieces BB IMPELLA CP SmartAssist Set (0048-0024-JP) or its equivalent 1 sets BC Cobalt XT DR MRI IS-1/DF- (DDPA 2D IS-1/DF4) or its equivalent pieces Delivery period : From 1, June, 202 through 31, May, 202 Delivery place : Asahikawa Medical University Hospital Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall : A not come under Article and of the Regulation concerning the Contract for Asahikawa Medical University Furthermore, minors, Person under Conservatorshi or Person under Assistance that obtained the consent necessary for concluding a contract may be applicable under cases of special reasons within the said clause, B have the Grade A, Grade B or Grade C qualification during fiscal 202 in the Hokkaido area in Sales of products for participating in tenders by Single qualification for every ministry and agency, C have the following Grade qualification, for each item in ⑶above, A~AW prove to have obtained the first-class license for selling drugs in accordance with The Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices, AX~BC prove to have registered with the relevant authorities, in accordance with The Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices, to initiate business of selling medical appliances, D not be currently under a suspension of business order as instructed by the President, The National University Corporation Asahikawa Medical University. Time limit of tender : 1 : 0 1, May, 202 Contact point for the notice : A~AW Ryuji Sato, Procurement Section, Accounting Division, Asahikawa Medical University, 2-1-1- Midorigaokahigashi Asahikawa-shi Hokkaido 078-851 Japan, TEL 0166-69-307 AX~BC Takashi Sunada, Procurement Section, Accounting Division, Asahikawa Medical University, 2-1-1- Midorigaokahigashi Asahikawa-shi Hokkaido 078-851 Japan, TEL 0166-69-306 ⑼ Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents.

Japan

2026-03-26